More Severe IBD Boosts Risk for Non-alcoholic Fatty Liver Disease, Italian Study Suggests

More Severe IBD Boosts Risk for Non-alcoholic Fatty Liver Disease, Italian Study Suggests
The risk that inflammatory bowel disease (IBD) patients will develop non-alcoholic fatty liver disease (NAFLD) increases as IBD worsens, according to Italian researchers. Their study “Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease,” appeared in the journal Cell Death & Disease. NAFLD is associated with higher risk of cirrhosis and hepatocellular carcinoma. Although the condition is more often associated with metabolism dysfunction and metabolic syndrome (MetS) — a cluster of factors that raises the risk for heart disease and other health problems, NAFLD can also be present with IBD. However, scientists generally don't know the clinical characteristics of these patients, or how NAFLD affects IBD. In their retrospective study, researchers at the University of Modena's Department of Internal Medicine assessed NAFLD's clinical and metabolic parameters in two groups — IBD patients and those without IBD — to identify specific signs for NAFLD in an IBD population. Of the 223 patients participating, 78 had both NAFLD and IBD; the remaining 145 patients were diagnosed with NAFLD only. Of the 78 with both conditions, 42 had Crohn's disease and 36 ulcerative colitis. Among IBD patients, 55.1 percent had extensive disease, while 33.3 percent had active disease lasting at least three months. In addition, 25 of the 34 patients with more than one disease flare per year had been treated with corticosteroids — either budesonide (Pulmicort) or beclomethasone (Qvar). Patients with NAFLD and IBD were generally younger than those with only NAFLD, the
Subscribe or to access all post and page content.